Strategic Prevention Framework for Prescription Drugs (SPF Rx)

Post Date

March 29th 2016

Application Due Date

May 31st 2016

Funding Opportunity Number

SP-16-006

CFDA Number(s)

93.243

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Number of Awards

25

Eligibility Categories

Other

Eligibility is limited to these entities because they have the greatest likelihood of achieving success through the SPF Rx grant program. Having completed the SPF process, these entities have the necessary experience and background for implementation: 1) an established state/tribal infrastructure and system in place└rooted in both the SABG and the SPF prevention model└that allows them to quickly build capacity in communities of need, mobilize those communities, and ensure accurate data collection and reporting at the community level; 2) integration of the SPF-based process into their overall state and tribal prevention systems, ensuring a strong, data-driven focus on identifying, selecting, and implementing effective, evidence-based prevention programs, policies, and practices; 3) experience in working collaboratively with communities to achieve substance misuse prevention goals; 4) familiarity and experience with the alignment of behavioral health with primary prevention; 5) a history of building comprehensive state and tribal level prevention systems over time; and 6) the required state run prescription drug monitoring program.

Funding

• Estimated Total Funding:

  $9290395

• Award Range:

  $0 - $371616

Grant Description

The SPF Rx grant program provides an opportunity for states, U.S. territories, pacific jurisdictions (herein referred to as ЯstatesН), and tribal entities that have completed a Strategic Prevention Framework State Incentive Grant (SPF SIG) to target the priority issue of prescription drug misuse. The program is designed to raise awareness about the dangers of sharing medications and work with pharmaceutical and medical communities on the risks of overprescribing to young adults. SPF Rx will also raise community awareness and bring prescription drug abuse prevention activities and education to schools, communities, parents, prescribers, and their patients. In addition, SAMHSA will track reductions in opioid overdoses and the incorporation of Prescription Drug Monitoring Program (PDMP) data into needs assessments and strategic plans as indicators of the programмs success. PDMPs are state-run databases used to track the prescribing and dispensing of controlled prescription drugs to patients. They are designed to monitor this information for suspected abuse or diversion (i.e., channeling drugs into illegal use), and can give a prescriber or pharmacist critical information regarding a patientмs controlled substance prescription history. State applicants must have a fully operational PDMP in order to apply for the SPF Rx program. Tribes must coordinate with the state run PDMPs to identify opportunities for collaboration that will limit overprescribing in tribal communities.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  Substance Abuse and Mental Health Services Admin

• Agency Contact:

  Eileen Bermudez
  Office of Financial Resources, Division of Grants Management
  Substance Abuse and Mental Health Services Administration
  Rockville, Maryland 20857
  (240) 276-1412

• Agency Mailing Address:

  FOACSAP@samhsa.hhs.gov

• Agency Email Address:

  FOACSAP@samhsa.hhs.gov

• More Information:

  Strategic Prevention Framework for Prescription Drugs (SPF Rx)